UNSPSC 51383510: Ketorolac tromethamine

This classification denotes a cyclooxygenase inhibitor with the molecular formula C15H13NO3.C4H11NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4EVE5946BQ, chemically known as 1h-pyrrolizine-1-carboxylic acid, 5-benzoyl-2,3-dihydro, (+-)-, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) but more generally known as ketorolac trometamol, which bears US NIH Compound Identifier 84003.

UNSPSC 51383510 Ketorolac tromethamine is a Commodity code that maps poorly to the recent state and local opportunities posted under it. The source shows no solicitations actually seeking ketorolac tromethamine or other branded or generic NSAIDs; instead, the opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmaceutical contracting strategy, and generic multi-source pharmaceutical supply agreements spanning a much broader product scope. The code appears to be a mistagging in at least one issuing body's system, and ketorolac tromethamine itself does not surface as an active procurement focus in the recent state and local market.

The three opportunities show activity across state health agencies and cooperative purchasing vehicles rather than narrowly focused NSAID procurement. Seminole County, Florida issued an IFB in June 2026 for naloxone and drug deactivation systems with a July 26, 2023 response deadline. The Texas Health and Human Services Commission posted an RFI in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, released an RFP in January 2026 due March 26, 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products distributed to participating state and local facilities, including Oregon, with pricing weighted at 75 percent of the evaluation and contract effectiveness set for July 1, 2026. Given the mismatch between the ketorolac tromethamine commodity code and the actual work being solicited, firms pursuing pharmaceutical supply contracts should monitor broader generic drug and OTC product codes rather than this specific narrow pharmaceutical commodity.